From stem cells to alien life: The big scientific breakthroughs of 2010

New hope for blocking HIV; A breast cancer vaccine?; Stem-cell therapy used in paralyzed patient; Life takes on a new form

New hope for blocking HIV

A vaccine for HIV remains elusive, but scientists are making progress with other means of preventing infections by the virus that causes AIDS. In a two-year clinical trial, South African women cut their risk of infection in half when they regularly used an inexpensive vaginal gel containing tenofovir, a medication widely used to treat AIDS. It’s the first time a gel containing a microbicide has been found to work against HIV, and its success means that women no longer need to solely rely on men to wear a condom. Meanwhile, another drug commonly used to treat the AIDS virus in infected patients was shown to block infection altogether in sexually active gay men if taken daily. Three-quarters of subjects remained uninfected after a year if they regularly took the AIDS drug Truvada. The results “represent a major advance in HIV-prevention research,” says Kevin Fenton, a physician with the Centers for Disease Control and Prevention. “For the first time, we have evidence that a daily pill used to treat HIV is partially effective for preventing HIV.”

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us